Intelligent Bio Solutions Inc. (NASDAQ: INBS): Pioneering Advances in Medical Technology – Full Analysis Inside!

Intelligent Bio Solutions Inc. (NASDAQ: INBS): Pioneering Advances in Medical Technology - Full Analysis Inside!

In recent years, the medical technology industry has experienced significant growth, drawing consistent interest from investors. An intriguing company in this sector worth considering is Intelligent Bio Solutions Inc. (NASDAQ: INBS). The company is renowned for developing the Intelligent Fingerprinting Drug Screening System, offering a novel and rapid solution for drug screening. See Complete Report Here 

Intelligent Bio Solutions (NASDAQ: INBS) announced today unaudited revenue figures for the first quarter of 2024, reporting an impressive 80% increase compared to the same period last year. For the nine-month period ending March 31, 2024, the company expects unaudited revenue of around $2.38 million, showing a substantial 193% growth from the previous year. INBS is optimistic about its cartridge and reader sales, projecting a 17% increase in cartridge sales and a 20% rise in reader sales for Q1 2024, representing their highest quarterly cartridge sales since acquiring Intelligent Fingerprinting Limited in 2022. Looking ahead, INBS anticipates continued growth, with expected cartridge and reader sales increases of 25% and 63%, respectively, from July 1, 2023, to March 31, 2024, compared to the same period the prior year.

This year, it was announced that the company had forged a collaboration with Cliantha Research to conduct a pharmacokinetic (PK) study as part of the FDA 510(k) pathway for its system. The initial phase of this study will involve recruiting up to 40 healthy adults as participants. The recruitment process is scheduled to take place throughout March and April 2024. The studies are set to begin in May 2024, with sample analysis expected to conclude by June 2024. 

Moreover, the management is confident that their renewed internal focus will yield higher-quality accounts this year. 

The Intelligent Fingerprinting Drug Screening System stands out as a distinctive product due to its compact and portable design, making it ideal for drug screening anytime, anywhere. Its unique feature lies in requiring only fingerprint sweat for analysis, enabling quick and non-invasive sample collection. 

The sample collection process doesn't necessitate expert supervision and can be efficiently completed at a low cost within a short timeframe. This streamlined process could offer significant benefits, especially for large organizations.

 

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content."TSR" is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. "TSR" authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. "TSR" has not been compensated to produce content related to "Any Companies" appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.